Abstract
The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of February 2019 in Porto, Portugal. Its intensive programme covered a wide-range of themes—including many of the hot topics, challenges, pitfalls and yet unmet needs in the field of multiple sclerosis (MS)—led by a number of well-acknowledged world experts. This meeting review summarizes the talks that took place during the congress, which focussed on issues in MS as diverse as the development and challenges of progressive MS, epidemiology, differential diagnosis, medical management, molecular research and imaging tools.
| Original language | English |
|---|---|
| Pages (from-to) | 281-300 |
| Number of pages | 20 |
| Journal | Neurology and Therapy |
| Volume | 9 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Dec 1 2020 |
Keywords
- Congress review
- Demyelinating diseases
- Multiple sclerosis
- Neurological diseases
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management : An Insight into the 5th International Porto Congress of Multiple Sclerosis. / Sá, María José; Soares dos Reis, Ricardo; Altintas, Ayse et al.
In: Neurology and Therapy, Vol. 9, No. 2, 01.12.2020, p. 281-300.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management
T2 - An Insight into the 5th International Porto Congress of Multiple Sclerosis
AU - Sá, María José
AU - Soares dos Reis, Ricardo
AU - Altintas, Ayse
AU - Celius, Elisabeth Gulowsen
AU - Chien, Claudia
AU - Comi, Giancarlo
AU - Graus, Francesc
AU - Hillert, Jan
AU - Hobart, Jeremy
AU - Khan, Gulfaraz
AU - Kissani, Najib
AU - Langdon, Dawn
AU - Leite, Maria Isabel
AU - Okuda, Darin T.
AU - Palace, Jacqueline
AU - Papais-Alvarenga, Regina María
AU - Mendes-Pinto, Inês
AU - Shi, Fu Dong
N1 - Funding Information: The conference was supported by Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva, all of which had no role in its organization or scientific programme. Medical writing assistance and publication Rapid Service Fee were funded by ROCHE. The authors are grateful to Dr. Catarina Santos and Springer Healthcare for help in the preparation of the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Maria José Sá has received consulting fees from Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva. Ricardo Soares dos Reis has received non-financial support for meeting attendance from Bayer, Biogen, Boehringer Ingelheim, Daiichi Sankyo, Eisai, GE Healthcare, Mylan, Novartis, Roche, Sanofi and Teva. Ayse Altintas has received speaker honoraria for non-promotional education events and travel grants from Merck, Teva and Novartis. Elisabeth Gulowsen Celius has received personal compensation for serving on scientific advisory boards for Almirall, Biogen, Merck, Novartis, Genzyme and Teva; and has received speaker honoraria from Biogen, Genzyme, Roche, Novartis, Merck and Teva. Her department has received unrestricted research grants from Biogen, Novartis and Genzyme. Giancarlo Comi reports financial activities outside the submitted work from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGgA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman-La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday and Excemed. Francesc Graus reports royalties from Euroimmun for the use of IgLON5 as a diagnostic test and honoraria for assistant editor of MedLink Neurology. Jan Hillert reports, outside the submitted work, personal compensation for serving on scientific advisory boards for Sandoz, Biogen, Merck KGaA, Novartis, Sanofi-Genzyme and Celgene; has received speaker honoraria from Biogen, Sanofi-Genzyme, Novartis, Merck KGaA and Teva; and has received unrestricted research grants from Biogen, and commissioned research from Novartis, Sanofi-Genzyme, Merck and Roche. Jeremy Hobart has received consulting/advisor fees, honoraria and research support from Acorda, Biogen, Genzyme/Sanofi-Genzyme, Global Blood Therapeutics, Merck Serono, MS Academy, Novartis, Oxford Pharmagenesis, Roche, Tigercat and Vanita. Dawn Langdon has received grants from Merck and Novartis, and has received consulting/advisor fees from Merck, Teva, Bayer, Novartis, Biogen and Almirall. Darin T Okuda reports personal fees from Alexion, Biogen, Celgene, EMD Serono, Genentech, Genzyme and TG Therapeutics, and grants from Biogen, EMD Serono and Genentech, outside the submitted work. Jacqueline Palace reports grants from Merck Serono, Chugai, MedImmun, Alexion and Abide, and personal fees from Merck Serono, Teva, Chugai, MedImmun, Alexion, Novartis, Roche, Abide, Medday, Argenx, Mitsubishi, UCB and Viela Bio, outside the submitted work. In addition, Dr. Palace has a patent (issued through Isis Pharmaceuticals; Diagnosing Multiple Sclerosis) that is not related to present work. Regina María Papais-Alvarenga reports financial support for participation in neurology meetings/congresses, conferences and medical boards from Teva, Merck, Genzyme, Bayer Schering, Novartis, Biogen Idec and participation in clinical trials sponsored by Novartis, Biogen Idec and Roche. Ines Mendes-Pinto reports personal grant from the European Commission, Marie Curie COFUND Programme. Claudia Chien, Gulfaraz Khan, Najib Kissani, Maria Isabel Leite and Fu-Dong Shi report no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. Funding Information: The conference was supported by Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva, all of which had no role in its organization or scientific programme. Medical writing assistance and publication Rapid Service Fee were funded by ROCHE. Publisher Copyright: © 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of February 2019 in Porto, Portugal. Its intensive programme covered a wide-range of themes—including many of the hot topics, challenges, pitfalls and yet unmet needs in the field of multiple sclerosis (MS)—led by a number of well-acknowledged world experts. This meeting review summarizes the talks that took place during the congress, which focussed on issues in MS as diverse as the development and challenges of progressive MS, epidemiology, differential diagnosis, medical management, molecular research and imaging tools.
AB - The 5th International Porto Congress of Multiple Sclerosis took place between the 14th and 16th of February 2019 in Porto, Portugal. Its intensive programme covered a wide-range of themes—including many of the hot topics, challenges, pitfalls and yet unmet needs in the field of multiple sclerosis (MS)—led by a number of well-acknowledged world experts. This meeting review summarizes the talks that took place during the congress, which focussed on issues in MS as diverse as the development and challenges of progressive MS, epidemiology, differential diagnosis, medical management, molecular research and imaging tools.
KW - Congress review
KW - Demyelinating diseases
KW - Multiple sclerosis
KW - Neurological diseases
UR - http://www.scopus.com/inward/record.url?scp=85087974414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087974414&partnerID=8YFLogxK
U2 - 10.1007/s40120-020-00202-7
DO - 10.1007/s40120-020-00202-7
M3 - Review article
AN - SCOPUS:85087974414
VL - 9
SP - 281
EP - 300
JO - Neurology and Therapy
JF - Neurology and Therapy
SN - 2193-8253
IS - 2
ER -